Date: 2013-01-03
Type of information: Production agreement
Compound: two undisclosed vaccine candidates
Company: Sanofi Pasteur (France) Sutro Biopharma (USA - CA)
Therapeutic area: undisclosed
Type agreement: R&D
production
manufacturing
Action mechanism:
Disease: undisclosed
Details: Sanofi Pasteur and Sutro Biopharma, a biopharmaceutical company developing a new generation of protein therapeutics utilizing Sutro\'s cell-free protein synthesis technology, will colalborate to produce two undisclosed vaccine candidates. Details of the partnership were not disclosed. Four Oaks Partners advised Sutro on the transaction. Biopharma is developing a new generation of antibody drug conjugate therapeutics and bifunctional antibody-based therapeutics for targeted cancer therapies. These therapeutics will significantly extend the clinical impact of current oncology therapeutic approaches and are beyond what can be envisioned with current, cell-based expression technologies. Sutro\'s biochemical synthesis technology, which underpins these therapeutics, allows the rapid and systematic exploration of many protein drug variants to identify drug candidates. Once these product candidates are identified, production can be rapidly and predictably scaled up to commercial levels. Sutro has established a Good Manufacturing Practice (cGMP) facility for the production of clinical supplies of materials using its biochemical protein synthesis platform.
Financial terms:
Latest news:
